AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Cue Biopharma (NASDAQ:CUE)
1.61 USD
+0.120 8.054%Sponsored Reports
Loading...
| Previous Close (in USD) | 1.49 |
|---|---|
| Change | +0.120 8.054% |
| 52 W H/L (in USD) | 4.890/1.303 |
| EBITDA (in USD) | -50.802M |
| PE Ratio | -- |
| Volume | 571552 |
| Diluted Eps TTM | -1.07 |
| Total Assets (in USD) | 61.53M |
|---|---|
| Total Liabilities (in USD) | 24.445M |
| Revenue TTM (in USD) | 7.02M |
| Cash (in USD) | 48.514M |
| Market Cap (in USD) | 78.802 M |
| Revenue Per Share TTM | 0.149 |
| Gross Profit TTM (in USD) | 1.245M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Employees: 53
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Daniel R. Passeri J.D., M.Sc., MSc. | CEO & Director | 1961 |
| 2. | Dr. Anish Suri Ph.D. | Pres & Chief Scientific Officer | 1974 |
| 3. | Ms. Kerri-Ann Millar | Chief Financial Officer | 1970 |
| 4. | Dr. Ronald D. Seidel III, Ph.D. | Co-Founder | 1976 |
| 5. | Dr. Rodolfo J. Chaparro | Co-Founder & Sr. Advisor | 1973 |
| 6. | Dr. Steven C. Almo | Co-Founder and Chairman of Scientific & Clinical Advisory Board | 1961 |
| 7. | George B. Zavoico Ph.D. | VP of Investor Relations & Corp. Devel. | NA |
| 8. | Mr. Colin G. Sandercock J.D., MSE | Sr. VP, Gen. Counsel & Sec. | 1957 |
| 9. | Dr. Kenneth J. Pienta M.D. | Acting Chief Medical Officer | 1960 |
| 10. | Dr. Matteo Levisetti M.D. | Sr. VP of Clinical Devel. | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.520 0.474% | 107.975 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-4.800 4.372% | 112.15 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+28.360 5.998% | 483 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+0.310 0.037% | 824.94 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -53.01M | -43.666M | -44.579M | -36.286M | -38.155M |
| Minority Interest | - | - | - | - | - |
| Net Income | -52.796M | -44.161M | -44.785M | -36.698M | -38.98M |
| Selling General Administrative | 16.169M | 17.307M | 14.651M | 12.74M | 11.295M |
| Gross Profit | 1.245M | 14.941M | 3.154M | 3.458M | 1.143M |
| Reconciled Depreciation | 1.806M | -1.778M | 1.057M | 5.166M | 0.76M |
| Ebit | -53.225M | -41.934M | -45.043M | -41.935M | -38.697M |
| Ebitda | -50.767M | -43.712M | -43.985M | -36.769M | -37.937M |
| Depreciation And Amortization | 2.458M | -1.778M | 1.057M | 5.166M | 0.76M |
| Operating Income | -53.225M | -43.712M | -45.043M | -36.769M | -38.697M |
| Other Operating Expenses | 54.747M | 58.653M | 48.197M | 40.227M | 39.839M |
| Interest Expense | 0.714M | 1.732M | 0.464M | 5.649M | 0M |
| Tax Provision | 0M | 0.495M | 0.206M | 0.413M | 0.825M |
| Interest Income | 0.928M | 0.046M | 0.464M | 0.419M | 0.376M |
| Net Interest Income | 0.214M | 0.046M | 0.464M | 0.419M | 0.376M |
| Income Tax Expense | -0.214M | 0.495M | 0.206M | 0.412M | 0.825M |
| Total Revenue | 1.245M | 14.941M | 3.154M | 3.458M | 1.143M |
| Total Operating Expenses | 54.747M | 58.653M | 48.197M | 40.227M | 39.839M |
| Cost Of Revenue | - | - | - | 27.487M | 28.544M |
| Total Other Income Expense Net | 0.214M | 0.046M | 0.464M | 0.483M | 0.165M |
| Net Income From Continuing Ops | -53.01M | -44.161M | -44.785M | -36.699M | -38.98M |
| Net Income Applicable To Common Shares | -53.01M | -44.161M | -44.785M | -36.699M | -38.98M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 61.53M | 91.283M | 83.401M | 99.534M | 71.605M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 1.242M | 0.841M | 0.955M | 1.241M | 0.86M |
| Total Liab | 24.445M | 25.601M | 17.909M | 20.622M | 17.021M |
| Total Stockholder Equity | 37.085M | 65.683M | 65.492M | 78.911M | 54.584M |
| Other Current Liab | 4.137M | 3.554M | 4.62M | 2.787M | 2.227M |
| Common Stock | 0.047M | 0.043M | 0.032M | 0.03M | 0.027M |
| Capital Stock | 0.047M | 0.043M | 0.032M | 0.03M | 0.027M |
| Retained Earnings | -301.19M | -250.457M | -197.446M | -153.285M | -108.5M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 3.394M | 3.011M | 3.124M | 3.384M |
| Cash | 48.514M | 51.614M | 64.371M | 74.866M | 44.29M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 17.081M | 11.549M | 12.788M | 16.316M | 11.655M |
| Current Deferred Revenue | 2.112M | - | 0.645M | 6.681M | 4.097M |
| Net Debt | -33.819M | -32.299M | -54.318M | -67.72M | -38.494M |
| Short Term Debt | 7.331M | 5.263M | 4.932M | 4.777M | 4.448M |
| Short Long Term Debt | 3.963M | 1.963M | - | - | - |
| Short Long Term Debt Total | 14.695M | 19.316M | 10.053M | 7.146M | 5.796M |
| Other Stockholder Equity | 338.228M | 316.192M | 262.906M | 232.159M | 163.068M |
| Property Plant Equipment | - | 1.499M | 2.112M | 2.108M | 7.184M |
| Total Current Assets | 51.454M | 77.187M | 68.468M | 87.527M | 61.025M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 0M | 24.675M | 0M | 10.003M | 15.12M |
| Net Receivables | 1.698M | 0.057M | 3.143M | 1.417M | 0.755M |
| Long Term Debt | 4.202M | 8.035M | - | - | - |
| Inventory | 0M | - | - | - | 15.12M |
| Accounts Payable | 3.501M | 2.731M | 2.591M | 2.07M | 0.883M |
| Accumulated Other Comprehensive Income | - | -0.096M | - | 0.007M | -0.01M |
| Non Currrent Assets Other | 2.807M | 3.394M | 3.011M | 3.124M | 3.396M |
| Non Current Assets Total | 10.076M | 14.096M | 14.933M | 12.006M | 10.58M |
| Capital Lease Obligations | 6.53M | 9.318M | 10.053M | 7.146M | 5.796M |
| Long Term Debt Total | - | 8.035M | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -29.445M | 10M | -9.949M | -15.134M | -39.5M |
| Total Cashflows From Investing Activities | -24.61M | 9.109M | 4.456M | 3.447M | -20.354M |
| Total Cash From Financing Activities | 53.659M | 19.233M | 58.614M | 50.79M | 4.182M |
| Net Income | -53.01M | -44.161M | -44.785M | -36.699M | -38.98M |
| Change In Cash | -12.757M | -10.495M | 30.576M | 23.44M | -42.583M |
| Begin Period Cash Flow | 64.521M | 75.016M | 44.44M | 21M | 63.584M |
| End Period Cash Flow | 51.764M | 64.521M | 75.016M | 44.44M | 21M |
| Total Cash From Operating Activities | -41.806M | -38.837M | -32.494M | -30.797M | -26.411M |
| Depreciation | 1.806M | -1.778M | 1.057M | 5.166M | 0.76M |
| Other Cashflows From Investing Activities | 5.006M | 10.022M | 15M | 18.628M | 21M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | 4.79M | 4.853M | -0.51M | - |
| Sale Purchase Of Stock | 22.502M | 19.233M | -0.271M | -0.091M | 4.182M |
| Other Cashflows From Financing Activities | 14.5M | 1.849M | 2.203M | 1.882M | 0.013M |
| Capital Expenditures | 0.171M | 0.913M | 0.595M | 0.046M | 1.854M |
| Change In Working Capital | 0.356M | -4.387M | 1.232M | -1.489M | 4.211M |
| Other Non Cash Items | -0.454M | -0.026M | -0.563M | -4.278M | 0.345M |
| Free Cash Flow | -41.977M | -39.75M | -33.089M | -30.843M | -28.265M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 6 months ago | 1347078 |
| 2. | iShares Russell 2000 ETF | 6 months ago | 810192 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 6 months ago | 597569 |
| 4. | Fidelity Small Cap Index | 8 months ago | 365389 |
| 5. | iShares Russell 2000 Growth ETF | 6 months ago | 308836 |
| 6. | State St Russell Sm/Mid Cp® Indx NL Cl C | 6 months ago | 270100 |
| 7. | Fidelity Extended Market Index | 7 months ago | 250972 |
| 8. | DFA US Small Cap I | 7 months ago | 155551 |
| 9. | Vanguard Russell 2000 ETF | 6 months ago | 136230 |
| 10. | State St Russell Sm Cap® Indx SL Cl I | 6 months ago | 126100 |
| 11. | BlackRock Extended Mkt Composite | 1 year ago | 119467 |
| 12. | NT R2000 Growth Index Fund - NL | 10 months ago | 103758 |
| 13. | BlackRock Extended Equity Market K | 7 months ago | 103371 |
| 14. | NT R2000 Index Fund - NL | 7 months ago | 99593 |
| 15. | Nuveen Equity Index R6 | 7 months ago | 99010 |
| 16. | NT R2000 Growth Index Fund - L | 10 months ago | 81360 |
| 17. | NT R2000 Index Fund - DC - NL - 2 | 7 months ago | 79090 |
| 18. | Schwab Small Cap Index | 6 months ago | 74459 |
| 19. | iShares Micro-Cap ETF | 6 months ago | 74453 |
| 20. | Northern Trust Russell 2000 Growth Index | 7 months ago | 70460 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Bleichroeder LP | 7 months ago | 2755028 |
| 2. | Slate Path Capital LP | 7 months ago | 2402455 |
| 3. | BlackRock Inc | 10 months ago | 2338765 |
| 4. | Vanguard Group Inc | 7 months ago | 2283362 |
| 5. | Geode Capital Management, LLC | 10 months ago | 813285 |
| 6. | State Street Corporation | 10 months ago | 683695 |
| 7. | Robertson Stephens Wealth Management, LLC | 7 months ago | 478500 |
| 8. | Dimensional Fund Advisors, Inc. | 7 months ago | 431308 |
| 9. | Northern Trust Corp | 10 months ago | 381367 |
| 10. | Millennium Management LLC | 7 months ago | 362090 |
| 11. | Monaco Asset Management | 7 months ago | 334742 |
| 12. | Bank of America Corp | 10 months ago | 266227 |
| 13. | Advisory Research Inc | 7 months ago | 257225 |
| 14. | GSA Capital Partners LLP | 7 months ago | 209100 |
| 15. | Stifel Financial Corp | 7 months ago | 192592 |
| 16. | Nuveen Asset Management, LLC | 10 months ago | 191536 |
| 17. | Morgan Stanley - Brokerage Accounts | 10 months ago | 164706 |
| 18. | Goldman Sachs Group Inc | 10 months ago | 116648 |
| 19. | Squarepoint Ops LLC | 7 months ago | 116152 |
| 20. | Bank of New York Mellon Corp | 10 months ago | 109353 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Related Articles
Loading...
